- Home
- ATCX vs HURA Comparison
ATCX vs HURA Comparison
Compare ATCX & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | ATCX | HURA |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | Brazil | United States |
| Employees | 13 | 19 |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.5M | 87.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ATCX | HURA |
|---|---|---|
| Price | $6.15 | $1.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 65.1K | ★ 2.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.32 | $0.41 |
| 52 Week High | $14.01 | $4.41 |
Technical Indicators
Market Signals| Indicator | ATCX | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 43.92 | 60.40 |
| Support Level | $5.93 | $1.02 |
| Resistance Level | $7.85 | $1.55 |
| Average True Range (ATR) | 0.83 | 0.21 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 27.30 | 57.42 |
Price Performance
Historical ComparisonAbout ATCX Atlas Critical Minerals Corporation Common Stock
Atlas Critical Minerals Corporation, is a mineral exploration and development company focused on critical minerals projects and properties in Brazil. The company's portfolio principally includes mineral properties for rare earths, graphite, titanium, copper, uranium, and nickel. It also owns mineral rights for iron ore, quartzite, gold, and diamond properties. The company's project portfolio includes the Alto Paranaiba, Malacacheta, Arcos, Goias, Tocantins, Rio Piracicaba, and other projects.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.